Published in J Virol on January 17, 2007
SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology (2012) 2.92
Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR. Methods (2009) 1.91
HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration. Virology (2007) 1.61
Viral complementation allows HIV-1 replication without integration. Retrovirology (2008) 1.52
HIV integration site distributions in resting and activated CD4+ T cells infected in culture. AIDS (2009) 1.46
Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells. PLoS Pathog (2009) 1.45
Human immunodeficiency virus integrates directly into naive resting CD4+ T cells but enters naive cells less efficiently than memory cells. J Virol (2009) 1.45
Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A (2013) 1.41
Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency. PLoS Pathog (2012) 1.34
Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. J Virol (2007) 1.31
HIV reservoirs and latency models. Virology (2011) 1.29
A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One (2012) 1.23
The CXCR4-tropic human immunodeficiency virus envelope promotes more-efficient gene delivery to resting CD4+ T cells than the vesicular stomatitis virus glycoprotein G envelope. J Virol (2009) 1.20
Characterization of the behavior of functional viral genomes during the early steps of human immunodeficiency virus type 1 infection. J Virol (2009) 1.20
HIV-1 latency in actively dividing human T cell lines. Retrovirology (2008) 1.16
Primary cell model for activation-inducible human immunodeficiency virus. J Virol (2007) 1.10
CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One (2010) 1.09
Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells. J Virol (2009) 1.09
Exosomes from human immunodeficiency virus type 1 (HIV-1)-infected cells license quiescent CD4+ T lymphocytes to replicate HIV-1 through a Nef- and ADAM17-dependent mechanism. J Virol (2014) 1.09
High frequencies of resting CD4+ T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections. Proc Natl Acad Sci U S A (2009) 1.04
Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther (2010) 0.98
Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. PLoS One (2012) 0.94
Cocaine exposure enhances permissiveness of quiescent T cells to HIV infection. J Leukoc Biol (2013) 0.93
MicroRNA-mediated restriction of HIV-1 in resting CD4+ T cells and monocytes. Viruses (2012) 0.90
Differentially stimulated CD4+ T cells display altered human immunodeficiency virus infection kinetics: implications for the efficacy of antiviral agents. J Virol (2009) 0.90
Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes. PLoS Pathog (2013) 0.90
HIV restriction in quiescent CD4⁺ T cells. Retrovirology (2013) 0.88
Recent developments in human immunodeficiency virus-1 latency research. J Gen Virol (2013) 0.87
Quiescent T cells and HIV: an unresolved relationship. Immunol Res (2010) 0.87
A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy. J Virol (2015) 0.87
Cell activation and HIV-1 replication in unstimulated CD4+ T lymphocytes ingesting exosomes from cells expressing defective HIV-1. Retrovirology (2014) 0.84
Reduced cellular susceptibility to in vitro HIV infection is associated with CD4+ T cell quiescence. PLoS One (2012) 0.84
R5 HIV env and vesicular stomatitis virus G protein cooperate to mediate fusion to naive CD4+ T Cells. J Virol (2010) 0.81
Cocaine-mediated impact on HIV infection in humanized BLT mice. Sci Rep (2015) 0.78
TCR triggering transcriptionally downregulates CCR5 expression on rhesus macaque CD4(+) T-cells with no measurable effect on susceptibility to SIV infection. Virology (2010) 0.78
Restricted 5'-end gap repair of HIV-1 integration due to limited cellular dNTP concentrations in human primary macrophages. J Biol Chem (2013) 0.78
HIV-1 Vpr- and Reverse Transcription-Induced Apoptosis in Resting Peripheral Blood CD4 T Cells and Protection by Common Gamma-Chain Cytokines. J Virol (2015) 0.77
Distribution and fate of HIV-1 unintegrated DNA species: a comprehensive update. AIDS Res Ther (2017) 0.75
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 17.60
Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology (1995) 14.30
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature (2003) 13.24
DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10
Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature (1993) 11.15
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science (2003) 10.79
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell (2003) 9.48
HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J (1990) 9.34
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med (2003) 9.22
Human immunodeficiency virus type 1 spinoculation enhances infection through virus binding. J Virol (2000) 8.62
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med (2003) 8.40
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol (1995) 7.57
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell (2003) 7.42
Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science (1991) 7.15
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle. J Virol (1992) 5.78
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol (2003) 5.58
Retracted Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature (2005) 5.28
Role of the CD28 receptor in T-cell activation. Immunol Today (1990) 4.89
The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol (1995) 4.42
The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol (2003) 4.23
Progression to AIDS in the absence of a gene for vpr or vpx. J Virol (1995) 3.96
CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol (1991) 3.47
Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol (1998) 3.09
Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol (2002) 2.89
Mutational analysis of cell cycle arrest, nuclear localization and virion packaging of human immunodeficiency virus type 1 Vpr. J Virol (1995) 2.88
Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol (1995) 2.85
Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol (1998) 2.82
Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol (1997) 2.82
Molecular characterization, reactivation, and depletion of latent HIV. Immunity (2003) 2.80
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature (2003) 2.63
Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol (2005) 2.55
A sensitive, quantitative assay for human immunodeficiency virus type 1 integration. J Virol (2002) 2.54
Kinetics of human immunodeficiency virus type 1 reverse transcription in blood mononuclear phagocytes are slowed by limitations of nucleotide precursors. J Virol (1994) 2.36
Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol (1996) 2.33
Increased susceptibility of differentiated mononuclear phagocytes to productive infection with human immunodeficiency virus-1 (HIV-1). J Clin Invest (1992) 2.28
Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol (2005) 2.23
Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes. J Virol (1999) 1.97
Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. J Virol (1996) 1.80
Subcompartments of the G1 phase of cell cycle detected by flow cytometry. Proc Natl Acad Sci U S A (1980) 1.76
Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol (1995) 1.69
Highly purified CD25- resting T cells cannot be infected de novo with HIV-1. Proc Natl Acad Sci U S A (1997) 1.62
Human immunodeficiency virus type 1 DNA synthesis, integration, and efficient viral replication in growth-arrested T cells. J Virol (1993) 1.57
Long HIV type 1 reverse transcripts can accumulate stably within resting CD4+ T cells while short ones are degraded. AIDS Res Hum Retroviruses (2004) 1.51
Productive HIV-1 infection of macrophages restricted to the cell fraction with proliferative capacity. EMBO J (1994) 1.41
Role of CD25+ and CD25-T cells in acute HIV infection in vitro. J Immunol (1993) 1.19
Differential susceptibility of naive and memory CD4+ T cells to the cytopathic effects of infection with human immunodeficiency virus type 1 strain LAI. J Virol (1997) 1.11
Simultaneous three-color analysis of the surface phenotype and DNA-RNA quantitation using 7-amino-actinomycin D and pyronin Y. J Immunol Methods (1995) 1.07
Rapid expression of human immunodeficiency virus following activation of latently infected cells. J Virol (2006) 1.04
Molecular basis of cell cycle dependent HIV-1 replication. Implications for control of virus burden. Adv Exp Med Biol (1995) 0.95
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors. Proc Natl Acad Sci U S A (2007) 4.77
Identification of a SUMO-binding motif that recognizes SUMO-modified proteins. Proc Natl Acad Sci U S A (2004) 4.19
The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses (2004) 3.75
PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci U S A (2005) 2.93
Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer. J Virol (2008) 2.83
Molecular characterization, reactivation, and depletion of latent HIV. Immunity (2003) 2.80
Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol (2002) 2.63
Female human iPSCs retain an inactive X chromosome. Cell Stem Cell (2010) 2.59
A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood (2009) 2.25
Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21
Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A (2002) 2.14
Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity (2012) 2.13
Expression-based monitoring of transcription factor activity: the TELiS database. Bioinformatics (2004) 2.03
Controlling false-negative errors in microarray differential expression analysis: a PRIM approach. Bioinformatics (2003) 2.02
Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol (2002) 1.93
Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem (2012) 1.85
T lineage differentiation from human embryonic stem cells. Proc Natl Acad Sci U S A (2006) 1.64
Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc Natl Acad Sci U S A (2011) 1.61
Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc Natl Acad Sci U S A (2003) 1.58
HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood (2013) 1.51
Psychological risk factors for HIV pathogenesis: mediation by the autonomic nervous system. Biol Psychiatry (2003) 1.38
Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients. Hum Gene Ther (2004) 1.37
Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis (2002) 1.33
Serum levels of the homeostatic B cell chemokine, CXCL13, are elevated during HIV infection. J Interferon Cytokine Res (2005) 1.32
A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors. Genes Dev (2008) 1.27
Integrase interacts with nucleoporin NUP153 to mediate the nuclear import of human immunodeficiency virus type 1. J Virol (2009) 1.26
Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci U S A (2013) 1.24
Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. J Virol (2004) 1.20
HIV latency in the humanized BLT mouse. J Virol (2011) 1.19
Interleukin-15 but not interleukin-7 abrogates vaccine-induced decrease in virus level in simian immunodeficiency virus mac251-infected macaques. J Immunol (2007) 1.18
Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J Virol (2004) 1.17
Stress-induced enhancement of NF-kappaB DNA-binding in the peripheral blood leukocyte pool: effects of lymphocyte redistribution. Brain Behav Immun (2004) 1.17
CD4 on CD8(+) T cells directly enhances effector function and is a target for HIV infection. Proc Natl Acad Sci U S A (2004) 1.16
Generation and characterization of transgene-free human induced pluripotent stem cells and conversion to putative clinical-grade status. Stem Cell Res Ther (2013) 1.14
In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog (2012) 1.14
Activation of latent HIV using drug-loaded nanoparticles. PLoS One (2011) 1.10
Primary cell model for activation-inducible human immunodeficiency virus. J Virol (2007) 1.10
Human immunodeficiency virus integration efficiency and site selection in quiescent CD4+ T cells. J Virol (2009) 1.09
CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One (2010) 1.09
beta-Adrenoreceptors reactivate Kaposi's sarcoma-associated herpesvirus lytic replication via PKA-dependent control of viral RTA. J Virol (2005) 1.08
Engineering antigen-specific T cells from genetically modified human hematopoietic stem cells in immunodeficient mice. PLoS One (2009) 1.08
Eradication of HIV: current challenges and new directions. J Antimicrob Chemother (2008) 1.08
Activation of CD8 T cells induces expression of CD4, which functions as a chemotactic receptor. Blood (2002) 1.08
From skin biopsy to neurons through a pluripotent intermediate under Good Manufacturing Practice protocols. Stem Cells Transl Med (2011) 1.07
Role of human immunodeficiency virus type 1 integrase in uncoating of the viral core. J Virol (2010) 1.07
Rapid expression of human immunodeficiency virus following activation of latently infected cells. J Virol (2006) 1.04
Identifying and characterizing a functional HIV-1 reverse transcriptase-binding site on integrase. J Biol Chem (2009) 1.03
Molecular mechanisms by which human immunodeficiency virus type 1 integrase stimulates the early steps of reverse transcription. J Virol (2007) 1.03
Prostratin and bortezomib are novel inducers of latent Kaposi's sarcoma-associated herpesvirus. Antivir Ther (2005) 1.02
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res (2014) 1.01
Fidelity of target site duplication and sequence preference during integration of xenotropic murine leukemia virus-related virus. PLoS One (2010) 0.99
A self-renewal program controls the expansion of genetically unstable cancer stem cells in pluripotent stem cell-derived tumors. Stem Cells (2009) 0.98
The CD4 molecule on CD8+ T lymphocytes directly enhances the immune response to viral and cellular antigens. Proc Natl Acad Sci U S A (2005) 0.98
Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo. J Virol (2007) 0.98
HIV/AIDS eradication. Bioorg Med Chem Lett (2013) 0.98
Introduction of exogenous T-cell receptors into human hematopoietic progenitors results in exclusion of endogenous T-cell receptor expression. Mol Ther (2013) 0.97
Genome-wide binding map of the HIV-1 Tat protein to the human genome. PLoS One (2011) 0.95
High-throughput, sensitive quantification of repopulating hematopoietic stem cell clones. J Virol (2010) 0.95
A high-throughput method for cloning and sequencing human immunodeficiency virus type 1 integration sites. J Virol (2006) 0.94
Human immunodeficiency virus type 1 infection and replication in normal human oral keratinocytes. J Virol (2003) 0.94
Effect of latent human immunodeficiency virus infection on cell surface phenotype. J Virol (2002) 0.94
Pre-clinical evaluation of a 213Bi-labeled 2556 antibody to HIV-1 gp41 glycoprotein in HIV-1 mouse models as a reagent for HIV eradication. PLoS One (2012) 0.94
Generation of T lineage cells from human embryonic stem cells in a feeder free system. Stem Cells (2009) 0.93
Establishment and maintenance of HIV latency: model systems and opportunities for intervention. Future Virol (2010) 0.93
Cocaine exposure enhances permissiveness of quiescent T cells to HIV infection. J Leukoc Biol (2013) 0.93
CD4+ NK cells can be productively infected with HIV, leading to downregulation of CD4 expression and changes in function. Virology (2009) 0.93
HIV-1 infection in peripheral blood lymphocytes (PBLs) exposed to alcohol. Virology (2003) 0.90
Differentially stimulated CD4+ T cells display altered human immunodeficiency virus infection kinetics: implications for the efficacy of antiviral agents. J Virol (2009) 0.90
Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages. AIDS Res Hum Retroviruses (2008) 0.87
Quiescent T cells and HIV: an unresolved relationship. Immunol Res (2010) 0.87
CD4 expression on activated NK cells: ligation of CD4 induces cytokine expression and cell migration. J Immunol (2006) 0.87
Subcellular localization of feline immunodeficiency virus integrase and mapping of its karyophilic determinant. J Virol (2003) 0.86
Alcohol enhances HIV type 1 infection in normal human oral keratinocytes by up-regulating cell-surface CXCR4 coreceptor. AIDS Res Hum Retroviruses (2004) 0.85
Correct integration mediated by integrase-LexA fusion proteins incorporated into HIV-1. Mol Ther (2002) 0.85
Bioengineered vaults: self-assembling protein shell-lipophilic core nanoparticles for drug delivery. ACS Nano (2014) 0.84
HIV type 1 infection alters cytokine mRNA expression in thymus. AIDS Res Hum Retroviruses (2003) 0.84
Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging. J Clin Invest (2015) 0.83
Differential expression and interaction of host factors augment HIV-1 gene expression in neonatal mononuclear cells. Virology (2010) 0.83
A new functional role of HIV-1 integrase during uncoating of the viral core. Immunol Res (2010) 0.83
Macrophage differentiation from embryoid bodies derived from human embryonic stem cells. J Stem Cells (2009) 0.82
Phase I/II Clinical Trials Using Gene-Modified Adult Hematopoietic Stem Cells for HIV: Lessons Learnt. Stem Cells Int (2011) 0.82
Biology and pathophysiology of the new human retrovirus XMRV and its association with human disease. Immunol Res (2010) 0.81
Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. Antimicrob Agents Chemother (2011) 0.80
Stem cell-based approaches to treating HIV infection. Curr Opin HIV AIDS (2011) 0.80
Using the BLT humanized mouse as a stem cell based gene therapy tumor model. J Vis Exp (2012) 0.80
HIV latency is influenced by regions of the viral genome outside of the long terminal repeats and regulatory genes. Virology (2011) 0.78